precisionmedicineonline1d
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.
precisionmedicineonline2d
CHMP Recommends Approving Kisqali as Adjuvant Treatment for Early-Stage HER2-Negative Breast Cancer
The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.
precisionmedicineonline2d
Ontada Using Microsoft's AI Platform to Analyze Unstructured Data to Advance Precision Oncology
The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.
precisionmedicineonline2d
InformedDNA to Offer Phenomix Sciences' Obesity Test
The test is designed to identify various obesity phenotypes that doctors can use to personalize treatment plans.
precisionmedicineonline2d
Tenaya Therapeutics Expands Eligibility in Hypertrophic Cardiomyopathy Gene Therapy Trial
The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.
precisionmedicineonline3d
UCLA, Parker Institute for Cancer Immunotherapy Renew Research Alliance
Academic researchers' efforts to advance CAR T-cell immunotherapy research in this partnership recently received a boost from PICI.
precisionmedicineonline3d
Sanofi Invests €300M in Orano Med to Advance Radioligand Therapies
The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.
precisionmedicineonline3d
Cartesian Therapeutics Planning Phase III Trial for mRNA CAR T-Cell Therapy in Myasthenia Gravis
NEW YORK – Cartesian Therapeutics this week said it expects to discuss plans to initiate a Phase III trial of its investigational cell therapy, Descartes-08, for generalized myasthenia gravis (gMG) ...